Literature DB >> 7002187

Kinetics and metabolism of pyrazolones (propyphenazone, aminopyrine and dipyrone).

M Volz, H M Kellner.   

Abstract

1 Propyphenazone 220 mg was administered orally to volunteers. Maximum plasma concentrations between 1.5 microgram/ml and 3.5 micrograms/ml were found 30 min later. After comparable doses plasma concentrations in dog and rabbit were lower. The distribution volumes were 2 l/kg. 2 The major metabolic route of propyphenazone is demethylation. The main urinary metabolite is the enolglucuronide of N-(2)-demethylpropyphenazone. 3 Aminopyrine is rapidly and almost completely absorbed after oral administration. Maximum plasma concentrations of 10 microgram/ml are reached 1.5 h after a 500 mg dose. The biological half-life is 2-3 h, the relative distribution volume 60% on average, and binding to plasma proteins approximately 15%. 4 Unchanged aminopyrine is only excreted in small quantities. The major routes of metabolism are demethylation (4-methylaminoantipyrine and 4-aminoantipyrine) and acylation (4-acetyl and 4-formylaminoantipyrine). There are other biotransformation products. 5 After oral administration of [14C]-dipyrone 480 mg the maximum serum concentration of 13.4 +/- 0.8 microgram/ml occurred at 1-1.5 hours. 6 Dipyrone was not detectable in serum or urine. Four of seven metabolites were identified, and were identical with the main metabolites of aminopyrine.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7002187      PMCID: PMC1430198          DOI: 10.1111/j.1365-2125.1980.tb01813.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  28 in total

1.  Possible implication of a aldehyde metabolite in aminopyrine allergy.

Authors:  H Shimeno; H Yoshimura
Journal:  Xenobiotica       Date:  1972-09       Impact factor: 1.908

2.  [Quantitative urinary excretion of various aminopyrine metabolites in man].

Authors:  R Gradnik; L Fleischmann
Journal:  Pharm Acta Helv       Date:  1973-04

3.  [Aminopyrine-resorption and metabolism following rectal administration in man].

Authors:  L Fleischmann
Journal:  Pharm Acta Helv       Date:  1973-04

4.  [Studies on the effect of uremia on phenylbutazone and aminophenazone metabolism in man].

Authors:  H W Leber; A Harders; G Schütterle
Journal:  Klin Wochenschr       Date:  1972-12-01

5.  Rate of aminopyrine disappearance from plasma in young and aged humans.

Authors:  A Jori; E Di Salle; A Quadri
Journal:  Pharmacology       Date:  1972       Impact factor: 2.547

6.  [Pharmacokinetics of dimeylaminophenazone, 4-aminophenazone and phenazone in rats of various ages].

Authors:  W Klinger
Journal:  Arch Int Pharmacodyn Ther       Date:  1969-08

7.  [Studies on absorption and excretion of drugs. XVI. Determination of sulpyrin and its metabolites in the rat urine].

Authors:  H Nogami; M Hanano; S Awazu; K Imaoka
Journal:  Yakugaku Zasshi       Date:  1970-03       Impact factor: 0.302

Review 8.  [On the precursors and formation of methylrubazonic acid after ingestion of amidopyrine together with a review on the degradation of dimethylamino-phenyl-dimethyl-pyrazolone].

Authors:  F R Preuss; K M Voigt
Journal:  Arzneimittelforschung       Date:  1965-07

9.  [Metabolism of drugs. LXXI. The study on aminopyrine metabolism].

Authors:  H Yoshimura; H Shimeno; H Tsukamoto
Journal:  Yakugaku Zasshi       Date:  1970-11       Impact factor: 0.302

10.  [Biopharmaceutical and pharmacokinetic studies on metamizol-14C (Novalgin 14C) given to rats, dogs and men].

Authors:  O Christ; H M Kellner; G Ross; W Rupp; A Schwarz
Journal:  Arzneimittelforschung       Date:  1973-12
View more
  24 in total

1.  Selective venous vasodilator properties of the analgesic metamizole (dipyrone) in a human ex vivo model-implications for postoperative pain management.

Authors:  Markus Hoenicka; Hagen Gorki; Karl Traeger; Andreas Liebold
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2017-01-31       Impact factor: 3.000

2.  Comparison of in vitro and in vivo biotransformation in patients with liver disease of differing severity.

Authors:  H Kraul; J Truckenbrodt; A Huster; R Töpfer; A Hoffmann
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

3.  Plasma protein binding of dipyrone metabolites in man.

Authors:  E Zylber-Katz; L Granit; M Levy
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

4.  The TRPA1 channel mediates the analgesic action of dipyrone and pyrazolone derivatives.

Authors:  Romina Nassini; Camilla Fusi; Serena Materazzi; Elisabetta Coppi; Tiziano Tuccinardi; Ilaria M Marone; Francesco De Logu; Delia Preti; Raquel Tonello; Alberto Chiarugi; Riccardo Patacchini; Pierangelo Geppetti; Silvia Benemei
Journal:  Br J Pharmacol       Date:  2015-04-24       Impact factor: 8.739

Review 5.  Clinical pharmacokinetics of dipyrone and its metabolites.

Authors:  M Levy; E Zylber-Katz; B Rosenkranz
Journal:  Clin Pharmacokinet       Date:  1995-03       Impact factor: 6.447

Review 6.  Pyrazolone derivatives.

Authors:  R N Brogden
Journal:  Drugs       Date:  1986       Impact factor: 9.546

7.  Kinetics of hexobarbital and dipyrone in critical care patients receiving high-dose pentobarbital.

Authors:  G Heinemeyer; H J Gramm; W Simgen; R Dennhardt; I Roots
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

8.  Excretion of dipyrone metabolites in human breast milk.

Authors:  E Zylber-Katz; N Linder; L Granit; M Levy
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

9.  The effect of oral administration of dipyrone on the capacity of blood platelets to synthesize thromboxane A2 in man.

Authors:  A Eldor; E Zylber-Katz; M Levy
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

10.  Adjunct dipyrone in association with oral morphine for cancer-related pain: the sooner the better.

Authors:  José F Duarte Souza; Paula P Lajolo; Hélio Pinczowski; Auro Del Giglio
Journal:  Support Care Cancer       Date:  2007-09-06       Impact factor: 3.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.